[Management of hyperphosphatemia in CKD].
نویسندگان
چکیده
2.2 Na DRC estágios III e IV, a ingestão dietética de P deverá ser mantida em valores que atendam a recomendação de proteínas entre 0,6 e 0,8 g/kg/dia, porém não superior a 700 mg/dia se o P estiver acima dos valores normais e/ou se o paratormônio (PTH) estiver acima do nível recomendado para o estágio da DRC (Opinião). 2.3 Na DRC estágio V D, a ingestão dietética de P deverá estar entre 800 e 1.000 mg/dia, respeitando a recomendação de pelo menos 1,0 g de proteína/kg/dia (50% de proteína de alto valor biológico), desde que o P sérico não esteja abaixo de 3,5 mg/dL (Opinião).
منابع مشابه
Optimal management of hyperphosphatemia in end-stage renal disease: an Indian perspective
There has been an exponential increase in the incidence of diabetes and hypertension in India in the last few decades, with a proportional increase in chronic kidney disease (CKD). Preventive health care and maintenance of asymptomatic chronic disease such as CKD are often neglected by patients until they become symptomatic with fluid retention and uremia. Management of hyperphosphatemia in CKD...
متن کاملFGF-23 and Hyperphosphatemia in Dialysis Dependent Chronic Kidney Disease Patients
Dialysis dependent chronic kidney disease (CKD) has become a worldwide public health problem. It is known to increase patient morbidity and mortality risks which can cause major economic strain on the health-care systems. A population based study has shown that the incidence of this end stage renal disease (ESRD) in India was 160 per million population (p.m.p.) in the year 2008 [1]. One of the ...
متن کاملUse of Nicotinamide to Treat Hyperphosphatemia in Dialysis Patients
Hyperphosphatemia in chronic kidney disease (CKD) has been associated with elevated cardiovascular morbidity and mortality. Serum phosphate control remains a cornerstone of the clinical management of patients with CKD, in order to both attenuate the progression of secondary hyperparathyroidism or bone disease and (possibly) reduce the risk of vascular calcification. Despite technical improvemen...
متن کاملSecondary hyperparathyroidism: pathophysiology and treatment.
Secondary hyperparathyroidism is a frequently encountered problem in the management of patients with chronic kidney disease (CKD). Its pathophysiology is mainly due to hyperphosphatemia and vitamin D deficiency and resistance. This condition has a high impact on the mortality and morbidity of dialysis patients. Early diagnosis of secondary hyperparathyroidism is crucial in the management of pat...
متن کاملPrevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
Phosphate retention and, later, hyperphosphatemia are key contributors to chronic kidney disease (CKD)-mineral and bone disorder (MBD). Phosphate homeostatic mechanisms maintain normal phosphorus levels until late-stage CKD, because of early increases in parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF-23). Increased serum phosphorus, and these other mineral abnormalities, individ...
متن کاملUrinary Fractional Excretion of Phosphorus in Dogs with Spontaneous Chronic Kidney Disease
The increase of urinary fractional excretion of phosphorus (uFEP) may indicate phosphorus retention before the onset of hyperphosphatemia in the early stages of chronic kidney disease (CKD). The hypothesis of this study is whether uFEP may increase during the early stage of CKD as a compensatory mechanism to prevent hyperphosphatemia as well as whether hyperphosphatemia in the late stages is as...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
دوره 33 2 شماره
صفحات -
تاریخ انتشار 2011